𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Childhood anaplastic large cell lymphoma Ki-1/CD30: Clinicopathologic features of 19 cases

✍ Scribed by Rubie, Hervé ;Gladieff, Laurence ;Robert, Alain ;Gaubert, Isabelle ;Huguet, Françoise ;Rochaix, Philippe ;Pein, François ;Michel, Gérard ;Hoerni, Bernard ;Sommelet, Danièle ;Delsol, Georges


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
605 KB
Volume
22
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The authors report their cumulative experience of 19 children with what was previously called malignant histiocytosis (MH) but is now considered a true lymphoma and termed anaplastic large cell lymphoma (ALCL). The median age at diagnosis was 10 years and 6 months (range 2 y, 11 m, to 15 y). There were 13 males and 6 females. Most cases presented with fever, wasting and enlarged, often tender, lymph nodes. Other features were: fleeting cutaneous rashes in 7 cases; spontaneous regression of lymph nodes and skin lesions were seen in 5 patients. Bone marrow involvement was present in 3 cases, pulmonary infiltrate in 5, kidneys in 2, and central nervous system in none. The morphology of lymph node involvement was consistent with so‐called MH, a description originally applied to sinusoïdal infiltration by large „histiocytic”︁ cells. The coexpression of lymphoid activation antigens Ki‐1/CD 30 (18/19), epithelial membrane antigen EMA (18/19) and interleukin‐2 receptor/CD 25 (10/10) was the unifying immunopathologic feature of the neoplasm. Lineage antigens were not identifiable in 8/19 instances (null phenotype), while 10/19 expressed a T‐cell phenotype. None of the tumors expressed histiocytic markers. After variable, but intensive, combination chemotherapy, 15 children out of 18 evaluable achieved complete remission (CR). Among all patients, thirteen are still alive in CR (ten in first CR) with a median follow‐up of 5 years. This evaluation in the pediatric age group reinforces that so‐called MH is a lymphoid neoplasm, a conceptual change that could lead to improved understanding and therapy.© 1994 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


CD30 (Ki-1)-positive, anaplastic large c
✍ Charles W. Ross; Curtis A. Hanson; Bertram Schnitzer 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 764 KB

Background. There is great diversity in the clinical presentation of CD30 (Ki-1)-positive, anaplastic large cell lymphoma (ALCL). The authors report two patients in whom the clinical and morphologic features mimicked gastrointestinal carcinoma. Methods. Surgical pathology specimens were examined us

Anaplastic large cell Ki-1 lymphoma of b
✍ John K. C. Chan; Chi-Sing Ng; Pak-Kwan Hui; Wai-Tong Leung; Vai-Chong Sin; Tai-K 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 713 KB
Cytology of extranodal Ki-1 anaplastic l
✍ Maureen F. Zakowski; Helen Feiner; Michael Finfer; Patricia Thomas; Norma Wollne 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 819 KB

## Ki-I-positive anaplastic large-cell lymphoma (ALCL) is an uncommon neoplasm which may present with extranodal as well as nodal disease. By definition, the tumor cells are immunoreactive for Ki-1 or Ber-H2 antigen (CD30). There have been few published cytologic descriptions of this lymphoma, or o

Prognostic significance of p80 and visce
✍ Massimino, M. ;Spreafico, F. ;Luksch, R. ;Giardini, R. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract ## Background Between 1976 and 1998, CD30+anaplastic large cell lymphoma (ALCL) was diagnosed in 44 children (28 males, 16 females, age range 2.7–16.1 years, median 10). Up to 1993, 32 such children were treated according to a common chemotherapeutic protocol that stratified patients a

CD30+ anaplastic large-cell lymphoma wit
✍ Cherie H. Dunphy; Laura J. Gardner; Jose L. Manes; Christopher S. Bee; Kutay Tay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

CD13 is commonly expressed in hematopoietic malignancies of myelomonocytic origin and has less commonly been described in lymphoid neoplasms, including acute lymphoblastic leukemia, B-cell lymphoproliferative disorders, and plasma cell malignancies. Aberrant CD13 expression has rarely been described